# Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

> **NCT03379259** · PHASE1,PHASE2 · TERMINATED · sponsor: **BeiGene** · enrollment: 39 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** BGB-A333
- **DRUG:** BGB-A317

## Key facts

- **NCT ID:** NCT03379259
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-27
- **Primary completion:** 2020-09-08
- **Final completion:** 2020-09-08
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Study Was Terminated Early
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03379259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03379259, "Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03379259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*